Rowan T Chlebowski1, Wendy Barrington, Aaron K Aragaki, JoAnn E Manson, Gloria Sarto, Mary J OʼSullivan, Daniel Wu, Jane A Cauley, Lihong Qi, Robert L Wallace, Ross L Prentice. 1. 1Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 2Division of Public Health Issues, Fred Hutchinson Cancer Research Center, Seattle, WA 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA 4School of Medicine and Public Health, University of Wisconsin, Madison, WI 5Department of Obstetrics and Gynecology, University of Miami, Miami, FL 6Harbor-UCLA Medical Center, Department of Medicine, Torrance, CA 7School of Public Health, University of Pittsburgh, Pittsburgh, PA 8Division of Biostatistics, School of Medicine, University of California, Davis, CA 9College of Public Health, University of Iowa, Iowa City, IA.
Abstract
OBJECTIVE: In postmenopausal black women in the Women's Health Initiative randomized trial, estrogen alone reduced breast cancers but its comprehensive influence on health outcomes in black women is unknown. Therefore, we examined this issue in the Women's Health Initiative overall and by African ancestry. METHODS: A total of 1,616 black women with prior hysterectomy, including 1,061 with percent African ancestry determination, at 40 US centers were randomly assigned to conjugated equine estrogen (0.625 mg/d) or placebo for 7.2 years' (median) intervention with 13 years' cumulative follow-up. Coronary heart disease (CHD) and breast cancer were primary efficacy and safety outcomes, respectively. A global index also included stroke, colorectal cancer, hip fracture, pulmonary embolism, and death. RESULTS:Black women in the estrogen-alone group compared with black women in the placebo group had fewer breast cancers (17 vs 40, hazard ratio [HR] 0.47, 95% CI 0.26-0.82). In women with more than 80% African ancestry, breast cancer HR was lower (0.32, 95% CI 0.12-0.86, trend P = 0.04 for ancestry effect). Most other outcomes including CHD, stroke, hip fracture, and the global index were null with estrogen use in black women; a global index effect was more favorable in younger black women (HR 0.65, 95% CI 0.43-0.98). CONCLUSIONS: In black postmenopausal women with priorhysterectomy, estrogen alone significantly reduced breast cancer incidence with no adverse influence on CHD, venous thromboembolism, or all-cause mortality. Favorable estrogen-alone global index effects in younger black women warrant further study.
RCT Entities:
OBJECTIVE: In postmenopausal black women in the Women's Health Initiative randomized trial, estrogen alone reduced breast cancers but its comprehensive influence on health outcomes in black women is unknown. Therefore, we examined this issue in the Women's Health Initiative overall and by African ancestry. METHODS: A total of 1,616 black women with prior hysterectomy, including 1,061 with percent African ancestry determination, at 40 US centers were randomly assigned to conjugated equine estrogen (0.625 mg/d) or placebo for 7.2 years' (median) intervention with 13 years' cumulative follow-up. Coronary heart disease (CHD) and breast cancer were primary efficacy and safety outcomes, respectively. A global index also included stroke, colorectal cancer, hip fracture, pulmonary embolism, and death. RESULTS: Black women in the estrogen-alone group compared with black women in the placebo group had fewer breast cancers (17 vs 40, hazard ratio [HR] 0.47, 95% CI 0.26-0.82). In women with more than 80% African ancestry, breast cancer HR was lower (0.32, 95% CI 0.12-0.86, trend P = 0.04 for ancestry effect). Most other outcomes including CHD, stroke, hip fracture, and the global index were null with estrogen use in black women; a global index effect was more favorable in younger black women (HR 0.65, 95% CI 0.43-0.98). CONCLUSIONS: In black postmenopausal women with prior hysterectomy, estrogen alone significantly reduced breast cancer incidence with no adverse influence on CHD, venous thromboembolism, or all-cause mortality. Favorable estrogen-alone global index effects in younger black women warrant further study.
Authors: Ellen B Gold; Alicia Colvin; Nancy Avis; Joyce Bromberger; Gail A Greendale; Lynda Powell; Barbara Sternfeld; Karen Matthews Journal: Am J Public Health Date: 2006-05-30 Impact factor: 9.308
Authors: Piret Veerus; Sirpa-Liisa Hovi; Krista Fischer; Mati Rahu; Matti Hakama; Elina Hemminki Journal: Maturitas Date: 2006-02-28 Impact factor: 4.342
Authors: Lynn Rosenberg; Traci N Bethea; Emma Viscidi; Chi-Chen Hong; Melissa A Troester; Elisa V Bandera; Christopher A Haiman; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer Journal: J Natl Cancer Inst Date: 2015-11-26 Impact factor: 13.506
Authors: Daichi Shimbo; Lu Wang; Michael J Lamonte; Matthew Allison; Gregory A Wellenius; Anthony A Bavry; Lisa W Martin; Aaron Aragaki; Jonathan D Newman; Yael Swica; Jacques E Rossouw; JoAnn E Manson; Sylvia Wassertheil-Smoller Journal: J Hypertens Date: 2014-10 Impact factor: 4.844
Authors: Louise Lind Schierbeck; Lars Rejnmark; Charlotte Landbo Tofteng; Lis Stilgren; Pia Eiken; Leif Mosekilde; Lars Køber; Jens-Erik Beck Jensen Journal: BMJ Date: 2012-10-09
Authors: Rowan T Chlebowski; Garnet L Anderson; Aaron K Aragaki; JoAnn E Manson; Marcia L Stefanick; Kathy Pan; Wendy Barrington; Lewis H Kuller; Michael S Simon; Dorothy Lane; Karen C Johnson; Thomas E Rohan; Margery L S Gass; Jane A Cauley; Electra D Paskett; Maryam Sattari; Ross L Prentice Journal: JAMA Date: 2020-07-28 Impact factor: 56.272
Authors: Wei Shi; Xinlei Sheng; Kerry M Dorr; Josiah E Hutton; James I Emerson; Haley A Davies; Tia D Andrade; Lauren K Wasson; Todd M Greco; Yutaka Hashimoto; Joel D Federspiel; Zachary L Robbe; Xuqi Chen; Arthur P Arnold; Ileana M Cristea; Frank L Conlon Journal: Dev Cell Date: 2021-10-15 Impact factor: 13.417
Authors: Yilin Yoshida; Zhipeng Chen; Robin L Baudier; Marie Krousel-Wood; Amanda H Anderson; Vivian A Fonseca; Franck Mauvais-Jarvis Journal: Atherosclerosis Date: 2022-01-22 Impact factor: 5.162